Cooperative Localization for Multiple Robots based on Constraint Propagation Technique

Kyoung-Hwan Jo,Jihong Lee,Jiyong Kim

Abstract:

What problem does this paper attempt to address?

Coagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction

Kacper Karaban,Dorota Słupik,Aleksandra Reda,Magdalena Gajewska,Bartosz Rolek,Josip A Borovac,Panteleimon E Papakonstantinou,Dario Bongiovanni,Hanne Ehrlinder,William A E Parker,Aleksander Siniarski,Aleksandra Gąsecka,Josip A. Borovac,Panteleimon E. Papakonstantinou,William A.E. Parker

DOI: https://doi.org/10.1016/j.cpcardiol.2023.102127

IF: 16.464

2024-01-01

Current Problems in Cardiology

Abstract:Heart failure with preserved ejection fraction (HFpEF) is associated with multiple cardiovascular and noncardiovascular comorbidities and risk factors which increase the risk of thrombotic complications, such as atrial fibrillation, chronic kidney disease, arterial hypertension and type 2 diabetes mellitus. Subsequently, thromboembolic risk stratification in this population poses a great challenge. Since date from the large randomized clinical trials mostly include both patients with truly preserved EF, and those with heart failure with mildly reduced ejection fraction, there is an unmet need to characterize the patients with truly preserved EF. Considering the significant evidence gap in this area, we sought to describe the coagulation disorders and thrombotic complications in patients with HFpEF and discuss the specific thromboembolic risk factors in patients with HFpEF, with the goal to tailor risk stratification to an individual patient.

cardiac & cardiovascular systems
Systematic review and meta-analysis of stroke and thromboembolism risk in atrial fibrillation with preserved vs. reduced ejection fraction heart failure

Meijuan Zhang,Jie Zhou

DOI: https://doi.org/10.1186/s12872-024-04133-1

2024-09-18

Abstract:Background: Stroke and thromboembolism (TE) are significant complications in patients with atrial fibrillation (AF) and heart failure (HF). The impact of ejection fraction status on these risks remains unclear. This study aims to compare the risk of stroke and TE in patients with AF and HF with preserved (HFpEF) or reduced (HFrEF) ejection fraction. Methods: Literature search of PubMed, Embase, and Scopus databases was done for studies in adult (20 years or more) population of AF patients. Included studies had reported on the incidences of stroke and/or TE in patients with AF and associated HF with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). Cohort (prospective and retrospective), case-control studies, and studies that were based on secondary analysis of data from a trial were eligible for inclusion. Methodological quality was assessed using the Newcastle Ottawa Scale (NOS). Pooled hazard ratio (HR) with 95% confidence intervals (CI) were reported. Exploratory analysis was conducted based on the different cut-offs used to define HFrEF and HFpEF. Results: Twenty studies were analyzed. In the overall analysis, HFrEF in AF patients was associated with a significantly reduced risk of stroke and systemic TE (HR 0.88, 95% CI: 0.81, 0.96; n = 20, I2 = 86.6%), compared to HFpEF. However, most studies showed comparable risk of stroke among the two groups of patients except for two studies that had documented significantly reduced risk. Upon doing the sensitivity analysis by excluding these two studies, we found similar risk among the two group of subjects and with no heterogeneity (HR 1.01, 95% CI: 0.99, 1.03; n = 18, I2 = 0.0%). Exploratory analysis also showed that the risk of stroke and systemic thromboembolism was similar between those with HFpEF and HFrEF. Conclusion: The findings suggest that there is no significantly different risk of stroke and systemic thromboembolism in cases of AF with associated HFpEF or HFrEF. The finding does not support integration of left ventricular ejection fraction into stroke risk assessments.
Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model

T Kondo,P S Jhund,W T Abraham,J L Rouleau,M Packer,A S Desai,L V Kober,S D Solomon,M R Zile,S E Inzucchi,M N Kosiborod,M S Sabatine,P Ponikowski,F Martinez,J J V McMurray

DOI: https://doi.org/10.1093/eurheartj/ehac544.869

IF: 39.3

2022-10-16

European Heart Journal

Abstract:Background Heart failure (HF) ranks only second to atrial fibrillation (AF) as a cause of cardio-embolic stroke. Although anticoagulation reduces this risk in HF patients not in AF, the risk/benefit profile in relatively unselected populations is not favourable. Identification of patients at high risk of stroke may allow targeted and safer use of prophylactic anticoagulant therapy. Previously, we proposed a simple risk model for stroke in patients with HF and reduced ejection fraction (HFrEF). However, this model was derived from the two older trials (published in 2007/2008) and was not externally validated. Purpose We aimed to evaluate the current incidence of stroke in patients with HFrEF not in AF receiving modern pharmacological therapy and to validate our stroke prediction model. Methods We examined patient-level data from the PARADIGM-HF, ATMOSPHERE, and DAPA-HF trials. The risk score was calculated following: 7.39×(insulin-treated diabetes) + 6.53×(previous stroke) + 2.80×[ln(NT-proBNP (pg/ml)) × 0.1182]). According to the tertile of risk score, we divided the patients into three groups. Patients with AF were defined as those with either AF on an ECG or a history of AF. Results Of the total of 20,159 patients (who experienced 590 strokes) enrolled in the three trials, 12,751 patients did not have AF at baseline. Of those, 1,143 patients (9%) had insulin-treated diabetes, 873 patients (6.8%) had a history of the previous stroke, and the median value of NT-proBNP was 1,243 pg/ml. During a median follow-up of 2.0 years, 346 (2.7%) experienced a stroke (11.7 per 1000 patient-years). Figure 1 shows cumulative incidence function plots for stroke according to the tertile of risk score in 12,331 patients whose risk score can be calculated. The number of strokes in tertile 1, 2 and 3 were 80, 102 and 149, respectively. The 3-year cumulative incidence function rates of stroke were 2.0 (95% CI: 1.5–2.5) % in tertile 1, 2.6 (95% CI: 2.1–3.2) % in tertile 2, and 4.3 (95% CI: 3.6–5.2) % in tertile 3, respectively. In patients with tertile 3, the stroke rate was 18.1 per 1000 patient-years (compared to 20.1 per 1000 patient-years in patients with AF not receiving anticoagulation). In the Cox model, risk for stroke increased according to the elevation in the risk score (tertile 2: HR 1.47 (95% CI 1.09–1.97), tertile 3: HR 2.53 (95% CI 1.92–3.33), with tertile 1 as reference). Figure 2 shows calibration plots by comparing observed and predicted probabilities of stroke at 1 to 3 years. Discrimination evaluated using the overall c-index 0.84 (95% CI: 0.75–0.91) was good. Conclusions These findings validate a previously described predictive model and confirm that it is possible to identify a subset of HFrEF patients without AF who have a risk of stroke that approximates to that in patients with AF. In these patients, the risk/benefit balance might justify the use of prophylactic anticoagulation, but this hypothesis needs to be tested prospectively. Funding Acknowledgement Type of funding sources: Foundation.

cardiac & cardiovascular systems
The association of ischaemic stroke in patients with heart failure without atrial flutter/fibrillation

Yen-Lien Chou,Jun-Ting Liou,Cheng-Chung Cheng,Min-Chien Tsai,Wei-Shiang Lin,Shu-Meng Cheng,Cheng-Li Lin,Chin-Sheng Lin,Chia-Hung Kao

DOI: https://doi.org/10.1136/heartjnl-2019-315646

IF: 5.7

Heart

Abstract:Purpose: This study evaluated the association between ischaemic stroke (IS) and heart failure (HF) in the absence of atrial fibrillation (AF) or atrial flutter (AFL) using a population-based nation-wide cohort database. Method: Newly diagnosed patients with HF without previous stroke and acute myocardial infarction (AMI) were enrolled. Based on the propensity scores matching age, sex and all comorbidities, our studies comprised 12 179 patients with HF and 12 179 patients without HF. Cox proportion hazard regression models and competing-risk regression models were used to evaluate the risk of IS among patients with HF without AF or AFL. Results: In the multivariable analysis, older age (adjusted HR (95% CI)=1.05 (1.04 to 1.05)), male sex (adjusted HR (95% CI)=1.36 (1.24 to 1.50)), diabetes (adjusted HR (95% CI)=2.22 (1.97 to 2.49)) and hypertension (adjusted HR (95% CI)=1.60 (1.41 to 1.82)) were markedly associated with IS in patients with HF. The HF group had a markedly higher risk of IS than did the non-HF group (subdistribution HR (SHR)=1.51, 95% CI: 1.37 to 1.66) and AMI (SHR=3.40, 95% CI: 2.71 to 4.28). Additionally, according to the Kaplan-Meier analysis, patients with HF were at a significantly higher risk of cumulative incidence of IS and AMI than did patients with non-HF (p value of log-rank test <0.001). Conclusion: This study indicated that HF is a strong independent risk factor for IS, even in the absence of AF or AFL. Clinical physicians should investigate IS through routine screening and careful monitoring of patients with HF.
Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial

Patrick M Pullicino,Min Qian,Ralph L Sacco,Ron Freudenberger,Susan Graham,John R Teerlink,Douglas Mann,Marco R Di Tullio,Piotr Ponikowski,Dirk J Lok,Stefan D Anker,Gregory Y H Lip,Conrado J Estol,Bruce Levin,Jay P Mohr,John L P Thompson,Shunichi Homma,WARCEF Investigators

DOI: https://doi.org/10.1159/000365502

Abstract:Background and purpose: WARCEF randomized 2,305 patients in sinus rhythm with ejection fraction (EF) ≤ 35% to warfarin (INR 2.0-3.5) or aspirin 325 mg. Warfarin reduced the incident ischemic stroke (IIS) hazard rate by 48% over aspirin in a secondary analysis. The IIS rate in heart failure (HF) is too low to warrant routine anticoagulation but epidemiologic studies show that prior stroke increases the stroke risk in HF. In this study, we explore IIS rates in WARCEF patients with and without baseline stroke to look for risk factors for IIS and determine if a subgroup with an IIS rate high enough to give a clinically relevant stroke risk reduction can be identified. Methods: We compared potential stroke risk factors between patients with baseline stroke and those without using the exact conditional score test for Poisson variables. We looked for risk factors for IIS, by comparing IIS rates between different risk factors. For EF we tried cut-off points of 10, 15 and 20%. The cut-off point 15% was used as it was the highest EF that was associated with a significant increase in IIS rate. IIS and EF strata were balanced as to warfarin/aspirin assignment by the stratified randomized design. A multiple Poisson regression examined the simultaneous effects of all risk factors on IIS rate. IIS rates per hundred patient years (/100 PY) were calculated in patient groups with significant risk factors. Missing values were assigned the modal value. Results: Twenty of 248 (8.1%) patients with baseline stroke and 64 of 2,048 (3.1%) without had IIS. IIS rate in patients with baseline stroke (2.37/100 PY) was greater than patients without (0.89/100 PY) (rate ratio 2.68, p < 0.001). Fourteen of 219 (6.4%) patients with ejection fraction (EF) <15% and 70 of 2,079 (3.4%) with EF ≥ 15% had IIS. In the multiple regression analysis stroke at baseline (p < 0.001) and EF <15% vs. ≥ 15% (p = 0.005) remained significant predictors of IIS. IIS rate was 2.04/100 PY in patients with EF <15% and 0.95/100 PY in patients with EF ≥ 15% (p = 0.009). IIS rate in patients with baseline stroke and reduced EF was 5.88/100 PY with EF <15% decreasing to 2.62/100 PY with EF <30%. Conclusions: In a WARCEF exploratory analysis, prior stroke and EF <15% were risk factors for IIS. Further research is needed to determine if a clinically relevant stroke risk reduction is obtainable with warfarin in HF patients with prior stroke and reduced EF.
Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials

Amanda Lloji,Jayakumar Sreenivasan,Joel Novograd,Wilbert S. Aronow,Stephen Pan,Gregg M. Lanier

DOI: https://doi.org/10.1080/13543784.2022.2069009

2022-04-27

Expert Opinion on Investigational Drugs

Abstract:Heart failure with preserved ejection fraction (HFpEF) is a disease with a high prevalence. Accounting for more than 50% of all heart failure cases, it carries a significant mortality. There is a lack of therapeutic options that show improvement in morbidity and mortality. Certain novel therapies have shown a decrease in heart failure hospitalizations; however, this beneficial effect was more pronounced for heart failure patients with mildly reduced ejection fraction (EF).This review summarizes the pathophysiology of the disease to help elucidate the differences between heart failure with reduced ejection fraction (HFrEF), and HFpEF, which could explain why therapies are successful in one (rather than the other). This review focuses on non-standardized nomenclature across major trials, the challenges of finding a therapeutic agent for such a heterogeneous population, and identification of specific phenotypes that have different outcomes and could be a target for future therapies.Lack of standardized diagnostic criteria, associated with population heterogeneity, might explain why trials have failed to improve outcomes for patients with HFpEF. Standardizing phenotypes, recapitulating these phenotypes in animal models, and understanding the mechanisms of the disease at the molecular level could be the first steps in identifying promising therapeutic options.

pharmacology & pharmacy
Race-Ethnicity, Age, and Heart Failure in Ischemic Stroke

Chinwe Ibeh,Randolph S Marshall,Joshua Z Willey

DOI: https://doi.org/10.1016/j.jstrokecerebrovasdis.2024.107809

IF: 2.677

2024-06-08

Journal of Stroke and Cerebrovascular Diseases

Abstract:Objectives Race-ethnic disparities contribute to cardiovascular morbidity. Heart failure (HF) is highly prevalent in acute ischemic stroke (AIS) and associated with worse outcomes. We hypothesized race-ethnic differences exist in the prevalence of HF among patients with AIS, particularly in younger patients, and in a manner not fully explained by cardiovascular profiles. Methods Patients with AIS in the National Inpatient Sample (2016-2019) were categorized as young (<50 years), middle (50-64) and older (≥65) age. Interaction between age and race-ethnicity on the presence of comorbid HF was examined, adjusting for vascular risk factors. Effect modification on in-hospital mortality and prolonged hospitalization across race-ethnic groups and age was also examined. Results Of 398,470 AIS patients, 16.2% had HF. HF patients were older (73.7 vs 69.5 years, P <0.001), had a lower proportion of White, Hispanic and Asian/PI individuals but a larger proportion of patients of Black race (21.0 vs 16.4%, P < 0.001). Race-ethnicity modified the relationship between HF and age (P interaction <0.001). Stroke patients of Black race had the greatest odds of having HF across all age groups, however differences between Black and White patients were most pronounced in young adults (OR: 2.08, 95% CI: 1.91-2.27) after adjusting for vascular risk factors. Among patients with HF, Black race was associated with reduced risk of in-hospital mortality but greater likelihood of prolonged hospitalization at middle and older age. Conclusion HF is highly prevalent in stroke patients of Black race, particularly in younger cohorts, and in a manner not fully explained by cardiovascular profiles.

neurosciences,peripheral vascular disease
Ileostomy output and bile acid excretion after intraduodenal administration of oleic acid.

T. Hallgren,T. Oresland,H. Andersson,L. Hultén

DOI: https://doi.org/10.3109/00365529409094879

1994-11-01

Scandinavian Journal of Gastroenterology

Abstract:BACKGROUND Ileostomy output and small-intestinal transport are regulated by complex mechanisms, which the present study aimed to further elucidate. METHODS The time-related ileostomy output and bile acid excretion after intraduodenal administration of a fat solution (oleic acid, 3.5 g) was studied in 29 ileostomy patients. Eighteen patients had the entire small bowel preserved (group I), whereas 11 had various lengths of the ileum resected or bypassed (group II). RESULTS Intraduodenal fat administration resulted in a prompt and significant increase in ileostomy output in both groups. The accumulated 2-h output after fat administration amounted to 60% of the normal 24-h output in group I and 30% in group II. A marked increase in bile acid excretion preceded the flow response. The fat-induced response was abolished by administration of cholestyramine. CONCLUSIONS Bile acids seem to have important regulatory effects with regard to secretion/absorption and transport of small-bowel contents, affecting ileostomy output, with clinical implications in many patients.
Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta‐analysis

Garen Kroshian,Jacob Joseph,Scott Kinlay,Adelqui O. Peralta,Peter S. Hoffmeister,Jagmeet P. Singh,Matthew F. Yuyun

DOI: https://doi.org/10.1111/jce.16209

IF: 2.7

2024-02-14

Journal of Cardiovascular Electrophysiology

Abstract:Introduction Heart failure (HF) and atrial fibrillation (AF) frequently co‐exist. Contemporary classification of HF categorizes it into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF). Aggregate data comparing the risk profile of AF between these three HF categories are lacking. Methods We conducted a systematic review and meta‐analysis aimed at determining any significant differences in AF‐associated all‐cause mortality, HF hospitalizations, cardiovascular mortality (CV), and stroke between HFrEF, HFmrEF, and HFpEF. A systematic search of PubMed, EMBASE, and Cochrane Library databases until February 28, 2023. Data were combined using DerSimonian‐Laird random effects model. Results A total of 22 studies comprising 248 323 patients were retained: HFrEF 123 331 (49.7%), HFmrEF 40 995 (16.5%), and HFpEF 83 997 (33.8%). Pooled baseline AF prevalence was 36% total population, 30% HFrEF, 36% HFmrEF, and 42% HFpEF. AF was associated with a higher risk of all‐cause mortality in the total population with pooled hazard ratio (HR) = 1.13 (95% confidence interval [CI] = 1.07−1.21), HFmrEF (HR = 1.25, 95% CI = 1.05−1.50) and HFpEF (HR = 1.16, 95% CI = 1.09−1.24), but not HFrEF (HR = 1.03, 95% CI = 0.93−1.14). AF was associated with a higher risk of HF hospitalizations in the total population (HR = 1.29, 95% CI = 1.14−1.46), HFmrEF (HR = 1.64, 95% CI = 1.20−2.24), and HFpEF (HR = 1.46, 95% CI = 1.17−1.83), but not HFrEF (HR = 1.01, 95% CI = 0.87−1.18). AF was only associated with CV in the HFpEF subcategory but was associated with stroke in all three HF subtypes. Conclusions AF appears to be associated with a higher risk of all‐cause mortality and HF hospitalization in HFmrEF and HFpEF. With these findings, the paucity of data and treatment guidelines on AF in the HFmrEF subgroup becomes even more significant and warrant further investigations.

cardiac & cardiovascular systems
Interaction of Heart Failure and Stroke: A clinical consensus statement of the ESC Council on Stroke, the Heart Failure Association (HFA) and the ESC Working Group on Thrombosis

Wolfram Doehner,Michael Böhm,Giuseppe Boriani,Christina Christersson,Andrew JS Coats,Karl Georg Haeusler,Ian D Jones,Gregory Y.H. Lip,Marco Metra,George Ntaios,Gianluigi Savarese,Eduard Shantsila,Gemma Vilahur,Giuseppe Rosano

DOI: https://doi.org/10.1002/ejhf.3071

2023-11-02

European Journal of Heart Failure

Abstract:Heart failure (HF) is a major disease in our society that often presents with multiple comorbidities with mutual interaction and aggravation. The comorbidity of HF and stroke is a high risk condition that requires particular attention to ensure early detection of complications, efficient diagnostic workup, close monitoring, and consequent treatment of the patient. The bi‐directional interaction between the heart and the brain is inherent in the pathophysiology of HF where HF may be causal for acute cerebral injury, and ‐ in turn ‐ acute cerebral injury via imbalanced neural and neurovegetative control of cardiovascular regulation may induce or aggravate HF. The present document represents the consensus view of the ESC Council on Stroke, the Heart Failure Association and the ESC Working Group on Thrombosis to summarize current insights on pathophysiologic interactions of the heart and the brain in the comorbidity of HF and stroke. Principal aspects of diagnostic workup, pathophysiologic mechanisms, complications clinical management in acute conditions and in long‐term care of patients with the comorbidity are presented and state of the art clinical management and current evidence from clinical trials is discussed. Beside the physicians perspective, also the patients values and preferences are taken into account. Interdisciplinary cooperation of cardiologists, stroke specialists, other specialists and primary care physicians is pivotal to ensure optimal treatment in acute events and in continued long‐term treatment of these patients. Key consensus statements are presented in a concise overview on mechanistic insights, diagnostic workup, prevention and treatment to inform clinical acute and continued care of patients with the comorbidity of heart failure and stroke.

cardiac & cardiovascular systems
[Graves' disease complicated with systemic lupus erythematosus (SLE): a case report].

H. Yamaguchi,M. Fukuzaki,S. Uezono,J. Tanoue,Y. Yasumoto,W. Yamashita,K. Osaki,A. Nakashima,R. Harada,S. Hashimoto

1989-07-01

Abstract:A 25 year old man had been subjected to subtotal thyroidectomy under the diagnosis of Graves' disease. About a year later the patient developed systemic lupus erythematosus (SLE). Reports on cases of Graves' disease complicated with SLE have barely been observed so far. Consequently, the authors reckoned, with reference to the other literatures on the subject, our case worth reporting.
Re fl ectiondistributionsof texturedmonocrystalline silicon : implications for silicon solar cells

S. Baker-Finch,K. McIntosh

Abstract:A common misconception is that alkaline textured silicon solar cell surfaces are characterised by features that are pyramidal and bounded by {111} planes. In preference to the typical approach of observing scanning electron microscope images, we analyse reflection distributions from various pyramidal textures and find that {111} faceted pyramids are a poor approximation to the features on such surfaces. We conclude that features are hillocks, with an octagonal base. Furthermore, the characteristic base angle of the texture depends on the etchant and is closer to 50–52 than the commonly accepted value of 54.74 . Analyses of antireflection, light trapping, photogeneration and surface recombination properties of textured surfaces should take this feature morphology into account. The base angle has a strong influence on the hemispherical reflectance of the textured surface, with higher angles resulting in reduced reflectance. The influence of this reflection enhancement upon device performance is smallest when an optimised antireflection coating is applied; compared with an array of {111} faceted pyramids, a hillock morphology with 50 base angle results in a 0.2% reduction in photogenerated current in a typical cell. Additionally, as base angle is reduced, an encapsulant of increasingly higher refractive index is required to drive internal reflection at the air–glass interface of light initially reflected from the cell surface. The development of texturing processes resulting in higher base angles is encouraged. Copyright © 2012 John Wiley & Sons, Ltd.
Prevalence and incidence of stroke, white matter hyperintensities, and silent brain infarcts in patients with chronic heart failure: A systematic review, meta-analysis, and meta-regression

Sean Tan,Clare Elisabeth Si Min Ho,Yao Neng Teo,Yao Hao Teo,Mark Yan-Yee Chan,Chi-Hang Lee,Lauren Kay Mance Evangelista,Weiqin Lin,Yao-Feng Chong,Tiong-Cheng Yeo,Vijay Kumar Sharma,Raymond C. C. Wong,Benjamin Y. Q. Tan,Leonard L. L. Yeo,Ping Chai,Ching-Hui Sia

DOI: https://doi.org/10.3389/fcvm.2022.967197

IF: 3.6

2022-09-16

Frontiers in Cardiovascular Medicine

Abstract:Introduction: Heart failure (HF) is associated with ischemic stroke (IS). However, there are limited studies on the prevalence of IS, white matter hyperintensities (WMHs), and silent brain infarcts (SBIs). Furthermore, interaction with ejection fraction (EF) is unclear. Methods: We searched three databases ( viz ., PubMed, Embase, and Cochrane) for studies reporting the incidence or prevalence of IS, WMHs, and SBIs in HF. A total of two authors independently selected included studies. We used random-effects models, and heterogeneity was evaluated with I 2 statistic. Meta-regression was used for subgroup analysis. Results: In total, 41 articles involving 870,002 patients were retrieved from 15,267 records. Among patients with HF, the pooled proportion of IS was 4.06% (95% CI: 2.94–5.59), and that of WMHs and SBIs was higher at 15.67% (95% CI: 4.11–44.63) and 23.45% (95% CI: 14.53–35.58), respectively. Subgroup analysis of HFpEF and HFrEF revealed a pooled prevalence of 2.97% (95% CI: 2.01–4.39) and 3.69% (95% CI: 2.34–5.77), respectively. Subgroup analysis of WMH Fazekas scores 1, 2, and 3 revealed a decreasing trend from 60.57 % (95% CI: 35.13–81.33) to 11.57% (95% CI: 10.40–12.85) to 3.07% (95% CI: 0.95–9.47). The relative risk and hazard ratio of patients with HF developing IS were 2.29 (95% CI: 1.43–3.68) and 1.63 (95% CI: 1.22–2.18), respectively. Meta-regression showed IS prevalence was positively correlated with decreasing anticoagulant usage. Conclusion: We obtained estimates for the prevalence of IS, WMH, and SBI in HF from systematic review of the literature. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=255126, PROSPERO [CRD42021255126].

cardiac & cardiovascular systems
[Clinical target volume for preoperative radiotherapy of rectal cancers].

F. Lorchel,J. Bosset,B. Bartholomot,M. Baron,G. Mantion,E. Pélissier,O. Goubard,P. Maingon

Abstract:The total mesorectal excision allows the marked increase of the local control rate in rectal cancer. Therefore, the mesorectal space is the usual field for the spread of rectal cancer cells. It could therefore be considered as the clinical target volume in the preoperative plan by the radiation oncologist. We propose to identify the mesorectum on anatomical structures of a treatment-position CT scan.
Impact of heart failure on stroke mortality and recurrence

Tiberiu A Pana,Adrian D Wood,Jesus A Perdomo-Lampignano,Somsak Tiamkao,Allan B Clark,Kannikar Kongbunkiat,Joao H Bettencourt-Silva,Kittisak Sawanyawisuth,Narongrit Kasemsap,Mamas A Mamas,Phyo K Myint

DOI: https://doi.org/10.1136/heartasia-2018-011139

2019-04-20

Heart Asia

Abstract:Objective: We aimed to examine the impact of heart failure (HF) on stroke mortality (in-hospital and postdischarge) and recurrence in a national stroke cohort from Thailand. Methods: We used a large, insurance-based database including all stroke admissions in the public health sector in Thailand between 2004 and 2015. Logistic and Royston-Parmar regressions were used to quantify the effect of HF on in-hospital and long-term outcomes, respectively. All models were adjusted for age, sex and comorbidities and stratified by stroke type: acute ischaemic stroke (AIS) or intracerebral haemorrhage (ICH). Multistate models were constructed using flexible survival techniques to predict the impact of HF on the disease course of a patient with stroke (baseline-[recurrence]-death). Only first-ever cases of AIS or ICH were included in the multistate analysis. Results: 608 890 patients (mean age 64.29±13.72 years, 55.07% men) were hospitalised (370 527 AIS, 173 236 ICH and 65 127 undetermined pathology). There were 398 663 patients with first-ever AIS and ICH. Patients were followed up for a median (95% CI) of 4.47 years (4.45 to 4.49). HF was associated with an increase in postdischarge mortality in AIS (HR [99% CI] 1.69 [1.64 to 1.74]) and ICH (2.59 [2.07 to 3.26]). HF was not associated with AIS recurrence, while ICH recurrence was only significantly increased within the first 3 years after discharge (1.79 [1.18 to 2.73]). Conclusions: HF increases the risk of mortality in both AIS and ICH. We are the first to report on high-risk periods of stroke recurrence in patients with HF with ICH. Specific targeted risk reduction strategies may have significant clinical impact for mortality and recurrence in stroke.
Association of heart failure subtypes and atrial fibrillation: Data from the Atherosclerosis Risk in Communities (ARIC) study

Miriam A M Nji,Scott D Solomon,Lin Yee Chen,Amil M Shah,Elsayed Z Soliman,Aniqa B Alam,Vinita Subramanya,Alvaro Alonso,Miriam A.M. Nji,Scott D. Solomon,Amil M. Shah,Elsayed Z. Soliman,Aniqa B. Alam

DOI: https://doi.org/10.1016/j.ijcard.2021.07.006

IF: 4.039

2021-09-01

International Journal of Cardiology

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Aims</h3><p>To determine the prevalence and incidence of AF among HF subtypes in a biracial community-based cohort.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>We studied 6496 participants in the Atherosclerosis Risk in Community study (mean age, 75.8 ± 5.3, 59% women, 23% black) who attended the 2011–2013 visit. HF was identified from physician adjudicated diagnosis, hospital discharges, and self-report. HF subtypes were based on echocardiography. A left ventricular ejection fraction <40% represents HF with reduced ejection fraction (HFrEF), 40%–49% for HF with midrange ejection fraction (HFmEF), and ≥ 50% for HF with preserved ejection fraction (HFpEF). AF was ascertained through 2017 from study electrocardiograms, hospital discharges, and death certificates. Confounder-adjusted logistic regression and Cox models were used to estimate associations of HF subtype with prevalent and incident AF.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>Among eligible participants, 393 had HF (HFpEF = 232, HFmEF = 41, HFrEF = 35 and unclassified HF =85) and 735 had AF. Compared to those without HF, all HF subtypes were more likely to have prevalent AF [odds ratio (95% confidence interval (CI)) 7.4 (5.6–9.9) for HFpEF, 8.1 (4.3–15.3) for HFmEF, 10.0 (5.0–20.2) for HFrEF, 8.8 (5.6–14.0) for unclassified HF]. Among participants without AF at baseline (<em>n</em> = 5761), 610 of them developed AF. Prevalent HF was associated with increased risk of AF [hazard ratio (95%CI) 2.3 (1.6–3.2) for HFpEF, 5.0 (2.7–9.3) for HFmEF, 3.5 (1.7–7.6) for HFrEF, 1.9 (0.9–3.7) for unclassified HR].</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>AF and HF frequently co-occur, with small differences by HF subtype, underscoring the importance of understanding the interplay of these two epidemics and evaluating shared preventive and therapeutic strategies.</p>

cardiac & cardiovascular systems
Both HFpEF and HFmrEF Should be Included in Calculating CHA2DS2–VASc score: a Taiwanese Longitudinal Cohort

Chien-Chien Cheng,Pang-Shuo Huang,Jien-Jiun Chen,Fu-Chun Chiu,Sheng-Nan Chang,Yi-Chih Wang,Cho-Kai Wu,Juey-Jen Hwang,Chia-Ti Tsai

DOI: https://doi.org/10.1016/j.hrthm.2024.02.048

IF: 6.779

2024-02-01

Heart Rhythm

Abstract:BACKGROUND: Congestive heart failure (CHF) as a risk of stroke in AF patients mainly referred to patients with left ventricular systolic dysfunction (HFrEF). Whether this should include patients with preserved ejection fraction (HFpEF) is debatable.OBJECTIVE: To investigate the variation in stroke risk between atrial fibrillation (AF) patients with HFpEF, HFmrEF, and HFrEF for enhancing risk assessment and subsequent management strategies.METHODS: In a longitudinal study utilizing the National Taiwan University Hospital Integrated Medical Database (iMED), 8358 patients with AF were followed for 10 years (mean follow-up 3.76 years). The study evaluated the risk of ischemic stroke in patients with differing ejection fractions (EF) and CHA2DS2-VASc score, further using Cox models adjusted for risk factors of AF-related stroke.RESULTS: HFpEF and HFmrEF patients had a higher mean CHA2DS2-VASc score compared to HFrEF patients (4.30±1.729 vs. 4.15±1.736 vs 3.73±1.712, p<0.001) and higher risk of stroke during follow-up (HR 1.40 (1.161-1.688), p<0.001 for HFmrEF; HR 1.184 (1.075-1.303), p=0.001) after multivariable adjustment. In patients with lower CHA2DS2-VASc score (0-4), presence of any type of CHF increased ischemic stroke risk (HFrEF HR 1.568 (1.189-2.068), p=0.001; HFmrEF HR 1.890 (1.372-2.603), p<0.001; HFpEF HR 1.800 (1.526-2.123), p<0.001).CONCLUSION: After multivariate adjustment, HFpEF and HFmrEF showed a similar risk of stroke in AF patients. Therefore, it is important to extend the criteria for "C" in the CHA2DS2-VASc score to include HFpEF patients. In patients with less concomitant stroke risk factors, the presence of any subtype of CHF increases risk for ischemic stroke.

cardiac & cardiovascular systems
Heart failure with preserved ejection fraction and atrial fibrillation: clinical management in the context of recent therapeutic advances in heart failure and electrophysiology

Eunice Yang,Haroon Rashid

DOI: https://doi.org/10.3389/fcvm.2024.1349584

IF: 3.6

2024-01-29

Frontiers in Cardiovascular Medicine

Abstract:Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) have emerged as major age-related epidemics within cardiology. Both conditions carry overlapping symptomatology, and delineating between AF and HFpEF from a diagnostic standpoint is challenging as echocardiographic and biomarker assessments used to diagnose HFpEF may be impacted by AF. Indeed, these two conditions are commonly found in the same individual, so much so that AF has been used in proposed diagnostic criteria for HFpEF. The frequent concomitant presence of these two conditions is associated with poorer quality of life, exertional capacity, as well as increased risk for decompensated heart failure and all-cause mortality. Though these deleterious effects of AF in HFpEF patients are well described, we currently have only a superficial understanding of the complex interplay between these two conditions. Preliminary studies on intervening in AF in HFpEF are very small, with mixed data on whether modifying the natural history of AF can lead to improvement in heart failure (HF) outcomes in HFpEF. In this review, we will describe the clinical implications of carrying both cardiovascular conditions, address recent advances in HFpEF and AF, and highlight preliminary studies targeted at reduction of effects associated with AF burden in HFpEF.

cardiac & cardiovascular systems
Clinical characteristics and frequency of anticoagulation in patients with atrial fibrillation and heart failure: results of a retrospective big data analysis

M. A. Druzhilov,T. Yu. Kuznetsova,D. V. Gavrilov,A. E. Andreichenko,R. E. Novitsky

DOI: https://doi.org/10.15829/1728-8800-2023-3477

2023-03-15

CARDIOVASCULAR THERAPY AND PREVENTION

Abstract:Aim. To evaluate the clinical characteristics and frequency of prescribed anticoagulant therapy for patients with atrial fibrillation (AF) and heart failure (HF) in subjects of the Russian Federation based on a retrospective big data analysis using artificial intelligence technologies. Material and methods. For retrospective analysis, information was obtained from the Webiomed predictive analytics platform, which includes depersonalized data from electronic health records of outand/ or inpatients in 6 subjects of the Russian Federation, extracted using artificial intelligence technologies. From the database of patients with AF (n=144431), a group of individuals (n=20970) with an established diagnosis of HF and information on left ventricular ejection fraction (LVEF) was selected. Results. Patients with AF and HF (men, 43,7%; age 72,1±13,2 years; LVEF, 58,9±11,0%) had a history of smoking in 36,6% of cases, hypertension — in 86,7%, type 2 diabetes — in 26,6%, gout — in 2,7%, stage III and IV-V chronic kidney disease — in 50,9 and 15,6%, lower limb peripheral arterial disease — in 15,8%. The incidence of ischemic stroke, LV myocardial infarction and pulmonary embolism was 8,8, 14,7 and 2,4%, respectively. Anticoagulants, including direct oral ones, were administered to patients with AF and HF in 62,5% and 32,0% of cases, respectively. The frequency of their appointment did not significantly differ depending on LVEF. Conclusion. Patients with AF and HF are characterized by significant comorbidity, a higher incidence of cardiovascular events compared with the group of individuals with AF without HF, and an unsatisfactory percentage of anticoagulant therapy.
Comparison of Characteristics and Outcomes Between Acute Ischemic Stroke Patients with Different Types of Heart Failure.

Jiongxing Wu,Mingxi Chen,Huan Wang,Yuyi Zhu,Yaqi Chen,Shihong Zhang,Deren Wang

DOI: https://doi.org/10.1536/ihj.22-717

2024-01-01

International Heart Journal

Abstract:Acute ischemic stroke (AIS) can be complicated by heart failure involving preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF), and whether or not the prognosis differs between the 2 types of patients remains unclear. We compared the clinical characteristics and outcomes of the 2 types of patients at 3 months after the stroke. We retrospectively analyzed patients who, between 1 January 2018 and 1 January 2021, experienced AIS that was complicated by HFrEF or HFpEF. All patients had been prospectively registered in the Chengdu Stroke Registry. Poor outcome was defined as a modified Rankin Scale (mRS) score of 2-6 at 3 months. Univariate and binary logistic regression was used to assess whether HFpEF was associated with a significantly worse prognosis than HFrEF. Among the final sample of 108 patients (60.2% men; mean age, 73.08 +/- 10.82 years), 75 (69.4%) had HFpEF. Compared to HFrEF patients, those with HFpEF were older (P = 0.002), were more likely to have chronic kidney disease (P = 0.033), and were more likely to experience a poor outcome (P = 0.022). After adjustments, HFpEF was associated with significantly greater risk of poor outcome than HFrEF (OR 4.13, 95%CI 1.20-15.79, P = 0.029). However, rates of hemorrhagic transformation or mortality at 3 months after AIS did not differ significantly between the 2 types of heart failure (all P > 0.05). Patients with AIS involving HFpEF experience worse outcomes than those with HFrEF and therefore may require special monitoring and management. Our findings need to be verified in large prospective studies.

Cooperative Localization for Multiple Robots based on Constraint Propagation Technique

Coagulation Disorders and Thrombotic Complications in Heart Failure With Preserved Ejection Fraction

Systematic review and meta-analysis of stroke and thromboembolism risk in atrial fibrillation with preserved vs. reduced ejection fraction heart failure

Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model

The association of ischaemic stroke in patients with heart failure without atrial flutter/fibrillation

Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial

Heart failure with preserved ejection fraction: key stumbling blocks for experimental drugs in clinical trials

Race-Ethnicity, Age, and Heart Failure in Ischemic Stroke

Ileostomy output and bile acid excretion after intraduodenal administration of oleic acid.

Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta‐analysis

Interaction of Heart Failure and Stroke: A clinical consensus statement of the ESC Council on Stroke, the Heart Failure Association (HFA) and the ESC Working Group on Thrombosis

[Graves' disease complicated with systemic lupus erythematosus (SLE): a case report].

Re fl ectiondistributionsof texturedmonocrystalline silicon : implications for silicon solar cells

Prevalence and incidence of stroke, white matter hyperintensities, and silent brain infarcts in patients with chronic heart failure: A systematic review, meta-analysis, and meta-regression

[Clinical target volume for preoperative radiotherapy of rectal cancers].

Impact of heart failure on stroke mortality and recurrence

Association of heart failure subtypes and atrial fibrillation: Data from the Atherosclerosis Risk in Communities (ARIC) study

Both HFpEF and HFmrEF Should be Included in Calculating CHA2DS2–VASc score: a Taiwanese Longitudinal Cohort

Heart failure with preserved ejection fraction and atrial fibrillation: clinical management in the context of recent therapeutic advances in heart failure and electrophysiology

Clinical characteristics and frequency of anticoagulation in patients with atrial fibrillation and heart failure: results of a retrospective big data analysis

Comparison of Characteristics and Outcomes Between Acute Ischemic Stroke Patients with Different Types of Heart Failure.